CN1478790A - 乳头瘤病毒衣壳蛋白的原核制备和应用 - Google Patents
乳头瘤病毒衣壳蛋白的原核制备和应用 Download PDFInfo
- Publication number
- CN1478790A CN1478790A CNA021290709A CN02129070A CN1478790A CN 1478790 A CN1478790 A CN 1478790A CN A021290709 A CNA021290709 A CN A021290709A CN 02129070 A CN02129070 A CN 02129070A CN 1478790 A CN1478790 A CN 1478790A
- Authority
- CN
- China
- Prior art keywords
- polymer
- capsid protein
- albumen
- protein
- papilloma virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000565 Capsid Proteins Proteins 0.000 title claims abstract description 27
- 102100023321 Ceruloplasmin Human genes 0.000 title claims abstract description 27
- 241000700605 Viruses Species 0.000 title claims description 18
- 206010028980 Neoplasm Diseases 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title claims description 6
- 210000002445 nipple Anatomy 0.000 title 1
- 229920000642 polymer Polymers 0.000 claims abstract description 42
- 241001631646 Papillomaviridae Species 0.000 claims abstract description 34
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 24
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 230000014509 gene expression Effects 0.000 claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 17
- 229920001184 polypeptide Polymers 0.000 claims abstract description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 14
- 239000000427 antigen Substances 0.000 claims abstract description 8
- 102000036639 antigens Human genes 0.000 claims abstract description 8
- 108091007433 antigens Proteins 0.000 claims abstract description 8
- 230000002163 immunogen Effects 0.000 claims abstract description 8
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 14
- 241000701806 Human papillomavirus Species 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 11
- 229960005486 vaccine Drugs 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 230000004927 fusion Effects 0.000 claims description 7
- 241000282994 Cervidae Species 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 230000009465 prokaryotic expression Effects 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 241000701646 Kappapapillomavirus 2 Species 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 230000002389 anti-papilloma Effects 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 2
- 241000009328 Perro Species 0.000 claims 2
- 210000004102 animal cell Anatomy 0.000 claims 1
- 208000006379 syphilis Diseases 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 9
- 230000001580 bacterial effect Effects 0.000 abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 4
- 239000012634 fragment Substances 0.000 abstract description 3
- 101710132637 Protein C2 Proteins 0.000 abstract 1
- 101710132697 Protein L2 Proteins 0.000 abstract 1
- 101710195626 Transcriptional activator protein Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 229960004854 viral vaccine Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000000234 capsid Anatomy 0.000 description 6
- 208000003154 papilloma Diseases 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 208000029211 papillomatosis Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
- 241000701812 Bovine papillomavirus type 4 Species 0.000 description 2
- 108010058432 Chaperonin 60 Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000780272 Mammilla Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000005267 amalgamation Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101100209954 Human papillomavirus type 16 L1 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021432 Immunisation reaction Diseases 0.000 description 1
- 101150027802 L2 gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000001726 chromosome structure Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920006389 polyphenyl polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- -1 proprionates Chemical compound 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (8)
- 一.通过原核细胞特别是大肠杆菌表达和制备侵染人和重要经济动物的乳头瘤病毒(papilloma virus)L1或L2或L1+L2衣壳蛋白的技术方法,包括这些衣壳蛋白任何可溶性多聚体的技术方法。
- 二.权利要求一中的衣壳蛋白L1或L2或L1+L2的表达与制备包括以任何融合蛋白或非融合蛋白的方式原核表达的氨基酸自然全长序列或截短序列的L1和L2蛋白多肽,包括它们的任何形式的可溶性多聚体。
- 三.权利要求二中的L1或L2或L1+L2衣壳蛋白包括来自下列人乳头瘤病毒亚型或株系:HPV1,HPV2,HPV3,HPV4,HPV5,HPV6,HPV7,HPV8,HPV9,HPV10,HPV11,HPV12,HPV13,HPV14,HPV15,HPV16,HPV17,HPV18,HPV19,HPV20,HPV21,HPV22,HPV23,HPV24,HPV25,HPV26,HPV27,HPV28,HPV31,HPV33,HPV34,HPV35,HPV36,HPV37,HPV38,HPV42,HPV43,HPV44,HPV45,HPV51,HPV52,HPV56,HPV58,和HPV66;同时也包括来自下列动物乳头瘤病毒亚型或株系:牛(BPV1,BPV2,BPV3,BPV4),狗(COPV),兔(CRPV)和鹿(DPV)。
- 四.权利要求一、二、和三中所包含的L1或L2或L1+L2衣壳蛋白及其多聚体作为人体抗HPV病毒疫苗使用;用以预防和治疗任何HPV亚型侵染所引起的癌症或其他病变,包括子宫颈癌和梅毒。
- 五.权利要求一、二、和三中所包含的L1或L2或L1+L2衣壳蛋白及其多聚体作为牛、狗、兔或鹿等动物抗乳头瘤病毒的疫苗使用;用以预防和治疗由乳头瘤病毒侵染所引起的任何病变。
- 六.权利要求一、二、和三中所包含的L1或L2或L1+L2衣壳蛋白及其多聚体作为其他多种疫苗的研究和应用载体使用;通过蛋白质工程或基因工程将任何多肽抗原移植到L1蛋白上后制备成新的疫苗,用以预防和治疗人体与新疫苗相关的其他疾病。
- 七.权利要求一、二、和三中所包含的L1或L2或L1+L2衣壳蛋白及其多聚体作为免疫诊断抗原使用;用以检测生物样品中是否有抗乳头瘤病毒的抗体存在。
- 八.权利要求一、二、和三中所包含的L1或L2或L1+L2蛋白及其多聚体作为免疫原使用;用于在动物体或动物细胞系中诱发免疫反应并制备由特定免疫原所决定的特异性抗体,并用此类特异性抗体检测生物样品中是否带有乳头瘤病毒作为抗原存在。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021290709A CN1293093C (zh) | 2002-08-30 | 2002-08-30 | 乳头瘤病毒衣壳蛋白的原核制备和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021290709A CN1293093C (zh) | 2002-08-30 | 2002-08-30 | 乳头瘤病毒衣壳蛋白的原核制备和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1478790A true CN1478790A (zh) | 2004-03-03 |
CN1293093C CN1293093C (zh) | 2007-01-03 |
Family
ID=34143956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021290709A Expired - Lifetime CN1293093C (zh) | 2002-08-30 | 2002-08-30 | 乳头瘤病毒衣壳蛋白的原核制备和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1293093C (zh) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008134935A1 (fr) * | 2007-04-29 | 2008-11-13 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Protéines 18 l1 de type papillomavirus humain tronqué |
WO2008134934A1 (en) * | 2007-04-29 | 2008-11-13 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | A truncated l1 protein of human papillomavirus 16 |
WO2008145020A1 (en) * | 2007-05-29 | 2008-12-04 | Xiamen University | A truncated l1 protein of human papillomavirus 11 |
WO2008145021A1 (en) * | 2007-05-29 | 2008-12-04 | Xiamen University | A truncated l1 protein of human papillomavirus 6 |
CN102268076A (zh) * | 2010-07-02 | 2011-12-07 | 厦门大学 | 截短的人乳头瘤病毒52型l1蛋白 |
CN102286104A (zh) * | 2010-06-21 | 2011-12-21 | 中国疾病预防控制中心病毒病预防控制所 | Hpv6型l2n120e7e6融合蛋白基因、表达载体、方法、菌株和用途 |
WO2012159562A1 (zh) * | 2011-05-25 | 2012-11-29 | 厦门大学 | 截短的人乳头瘤病毒33型l1蛋白 |
CN104211782A (zh) * | 2013-06-04 | 2014-12-17 | 厦门大学 | 截短的人乳头瘤病毒45型l1蛋白 |
WO2017157172A1 (zh) * | 2016-03-15 | 2017-09-21 | 中国医学科学院基础医学研究所 | 一种乳头瘤病毒嵌合蛋白及其用途 |
CN112409478A (zh) * | 2020-11-24 | 2021-02-26 | 华科同济干细胞基因工程有限公司 | 一种广谱hpv抗体及其制备方法和应用 |
CN113528544A (zh) * | 2021-06-02 | 2021-10-22 | 郑州大学 | 编码可溶性hpv23 l1蛋白的基因及其重组质粒的构建与应用 |
CN114716562A (zh) * | 2021-01-04 | 2022-07-08 | 中国医学科学院基础医学研究所 | 一种人乳头瘤病毒58型嵌合蛋白及其用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1241636A (zh) * | 1999-07-05 | 2000-01-19 | 第一军医大学珠江医院 | 抗hpv16e6核酶质粒及其在人乳头瘤病毒与肿瘤治疗中的应用 |
-
2002
- 2002-08-30 CN CNB021290709A patent/CN1293093C/zh not_active Expired - Lifetime
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101570571B (zh) * | 2007-04-29 | 2012-07-11 | 北京万泰生物药业股份有限公司 | 截短的人乳头瘤病毒18型l1蛋白 |
WO2008134934A1 (en) * | 2007-04-29 | 2008-11-13 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | A truncated l1 protein of human papillomavirus 16 |
US9428555B2 (en) | 2007-04-29 | 2016-08-30 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated L1 protein of Human Papillomavirus type 16 |
US9364529B2 (en) | 2007-04-29 | 2016-06-14 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated L1 protein of human papillomavirus type 18 |
WO2008134935A1 (fr) * | 2007-04-29 | 2008-11-13 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Protéines 18 l1 de type papillomavirus humain tronqué |
CN101343314B (zh) * | 2007-05-29 | 2015-11-25 | 厦门大学 | 截短的人乳头瘤病毒11型l1蛋白 |
WO2008145020A1 (en) * | 2007-05-29 | 2008-12-04 | Xiamen University | A truncated l1 protein of human papillomavirus 11 |
CN101343315B (zh) * | 2007-05-29 | 2012-06-13 | 厦门大学 | 截短的人乳头瘤病毒6型l1蛋白 |
US10537629B2 (en) | 2007-05-29 | 2020-01-21 | Xiamen University | Truncated L1 protein of human papillomavirus type 11 |
US9943586B2 (en) | 2007-05-29 | 2018-04-17 | Xiamen University | Truncated L1 protein of human papillomavirus type 11 |
US8748127B2 (en) | 2007-05-29 | 2014-06-10 | Xiamen University | Truncated L1 protein of human papillomavirus type 6 |
US9745351B2 (en) | 2007-05-29 | 2017-08-29 | Xiamen University | Truncated L1 protein of human papillomavirus type 6 |
US9533035B2 (en) | 2007-05-29 | 2017-01-03 | Xiamen University | Truncated L1 protein of human papillomavirus type 11 |
US20100255021A1 (en) * | 2007-05-29 | 2010-10-07 | Xiamen University | Truncated l1 protein of human papillomavirus type 6 |
WO2008145021A1 (en) * | 2007-05-29 | 2008-12-04 | Xiamen University | A truncated l1 protein of human papillomavirus 6 |
CN102286104B (zh) * | 2010-06-21 | 2013-10-16 | 中国疾病预防控制中心病毒病预防控制所 | Hpv6型l2n120e7e6融合蛋白基因、表达载体、方法、菌株和用途 |
CN102286104A (zh) * | 2010-06-21 | 2011-12-21 | 中国疾病预防控制中心病毒病预防控制所 | Hpv6型l2n120e7e6融合蛋白基因、表达载体、方法、菌株和用途 |
US9499591B2 (en) | 2010-07-02 | 2016-11-22 | Xiamen University | Truncated L1 protein of human papillomavirus type 52 |
CN102268076A (zh) * | 2010-07-02 | 2011-12-07 | 厦门大学 | 截短的人乳头瘤病毒52型l1蛋白 |
US9249193B2 (en) | 2011-05-25 | 2016-02-02 | Xiamen University | Truncated L1 protein of human papillomavirus type 33 |
EP2716653A4 (en) * | 2011-05-25 | 2015-01-21 | Univ Xiamen | PROTEIN L1 TRUNCATED FROM HUMAN PAPILLOMAVIRUS TYPE 33 |
WO2012159562A1 (zh) * | 2011-05-25 | 2012-11-29 | 厦门大学 | 截短的人乳头瘤病毒33型l1蛋白 |
CN104211782A (zh) * | 2013-06-04 | 2014-12-17 | 厦门大学 | 截短的人乳头瘤病毒45型l1蛋白 |
CN104211782B (zh) * | 2013-06-04 | 2017-11-17 | 厦门大学 | 截短的人乳头瘤病毒45型l1蛋白 |
WO2017157172A1 (zh) * | 2016-03-15 | 2017-09-21 | 中国医学科学院基础医学研究所 | 一种乳头瘤病毒嵌合蛋白及其用途 |
CN112409478A (zh) * | 2020-11-24 | 2021-02-26 | 华科同济干细胞基因工程有限公司 | 一种广谱hpv抗体及其制备方法和应用 |
CN114716562A (zh) * | 2021-01-04 | 2022-07-08 | 中国医学科学院基础医学研究所 | 一种人乳头瘤病毒58型嵌合蛋白及其用途 |
CN114716562B (zh) * | 2021-01-04 | 2023-11-10 | 中国医学科学院基础医学研究所 | 一种人乳头瘤病毒58型嵌合蛋白及其用途 |
CN113528544A (zh) * | 2021-06-02 | 2021-10-22 | 郑州大学 | 编码可溶性hpv23 l1蛋白的基因及其重组质粒的构建与应用 |
CN113528544B (zh) * | 2021-06-02 | 2022-07-08 | 郑州大学 | 编码可溶性hpv23 l1蛋白的基因及其重组质粒的构建与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1293093C (zh) | 2007-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100532548C (zh) | 一种提高人乳头瘤病毒l1蛋白原核表达产率的方法 | |
US7482015B2 (en) | Optimized expression of HPV 45 L1 in yeast | |
CN100506999C (zh) | Hpv31l1在酵母中的优化表达 | |
US7976848B2 (en) | Optimized expression of HPV 58 L1 in yeast | |
US6551597B1 (en) | Vaccine compositions for human papillomavirus | |
KR101203403B1 (ko) | 효모에서 hpv 52 l1의 최적화된 발현 | |
WO2008098484A1 (fr) | Protéines l1 recombinantes du papillomavirus et leurs utilisations | |
CN1293093C (zh) | 乳头瘤病毒衣壳蛋白的原核制备和应用 | |
Merckel et al. | The structure of the bacteriophage PRD1 spike sheds light on the evolution of viral capsid architecture | |
CN106795518A (zh) | 人类乳头瘤病毒构建体 | |
CN101481408A (zh) | 防止高度聚合的重组人乳头瘤病毒l1蛋白的修饰序列 | |
Motevalli et al. | Supercharged green fluorescent protein delivers HPV16E7 DNA and protein into mammalian cells in vitro and in vivo | |
CN101481407A (zh) | 重组人乳头瘤病毒l1衣壳蛋白的修饰序列 | |
WO2021013078A1 (zh) | 嵌合的人乳头瘤病毒52型l1蛋白 | |
WO2021013079A1 (zh) | 嵌合的人乳头瘤病毒56型l1蛋白 | |
WO2021013070A1 (zh) | 嵌合的人乳头瘤病毒35型l1蛋白 | |
WO2021013077A1 (zh) | 嵌合的人乳头瘤病毒58型l1蛋白 | |
WO2021013063A1 (zh) | 嵌合的人乳头瘤病毒16型l1蛋白 | |
WO2021013076A1 (zh) | 嵌合的人乳头瘤病毒45型l1蛋白 | |
WO2021013075A1 (zh) | 嵌合的人乳头瘤病毒18型l1蛋白 | |
WO2021013062A1 (zh) | 嵌合的人乳头瘤病毒31型l1蛋白 | |
CN103819543A (zh) | 重组的人乳头瘤病毒6型l1蛋白及其用途 | |
CN104045695A (zh) | 重组的人乳头瘤病毒18型l1蛋白及其用途 | |
BR102020006846A2 (pt) | Peptídeos sintéticos miméticos a proteína l1 do hpv, método de diagnóstico de hpv, sistema de diagnóstico de hpv, composição farmacêutica e uso dos mesmos no tratamento ou profilaxia do hpv | |
CN1696152A (zh) | 大肠杆菌表达的人乳头瘤病毒16型l1e7重组蛋白 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: WEIHAI DISHAMATT BIOLOGICAL PRODUCTS CO., LTD. Free format text: FORMER OWNER: MA RUNLIN Free format text: FORMER OWNER: CHEN XIAOJIANG Effective date: 20050408 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050415 Address after: East Qingdao Road, Weihai, Henan Applicant after: Weihai Disha Matt Biological Products Co. Address before: Beijing city Chaoyang District Datun Science Park South 512 floor, No. 106 Applicant before: Ma Runlin Co-applicant before: Chen Xiaojiang |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: MA RUNLIN; APPLICANT Free format text: FORMER OWNER: WEIHAI DISHAMATT BIOLOGICAL PRODUCTS CO., LTD. Effective date: 20060421 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060421 Address after: 100107 Beijing city Chaoyang District Wankexingyuan 9 room No. 1505 Applicant after: Ma Runlin Co-applicant after: Chen Xiaojiang Address before: 264205, Qingdao Road, Weihai, East Henan Applicant before: Weihai Disha Matt Biological Products Co. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING KANGLEWEISHI BIOTECHNOLOGY CO.LTD. Free format text: FORMER OWNER: MA RUNLIN; CHEN XIAOJIANG Effective date: 20081010 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20081010 Address after: Room 10, Hongda North Road, Beijing economic and Technological Development Zone, 4121: 100176 Patentee after: BEIJING HEALTH GUARD BIOTECHNOLOGY Co.,Ltd. Address before: Beijing city Chaoyang District Wankexingyuan 9 Building Room 1505, zip code: 100107 Co-patentee before: Chen Xiaojiang Patentee before: Ma Runlin |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Ma Runlin Document name: Special business review memo Addressee: Ma Runlin Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice |
Addressee: Ma Runlin Document name: Notification to Pay the Fees Addressee: Ma Runlin Document name: Notification of Termination of Patent Right |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: Longsheng industrial park No. 7 100176 street Beijing Rongchang economic and Technological Development Zone No. 2 building 201, unit 202 Patentee after: BEIJING HEALTH GUARD BIOTECHNOLOGY Co.,Ltd. Address before: 4121 room 10, Hongda North Road, Beijing economic and Technological Development Zone, 100176 Patentee before: BEIJING HEALTH GUARD BIOTECHNOLOGY Co.,Ltd. |
|
C53 | Correction of patent of invention or patent application | ||
C56 | Change in the name or address of the patentee |
Owner name: BEIJING HEALTH GUARD BIOTECHNOLOGY CO., LTD. Free format text: FORMER NAME: BEIJING HEALTHY GUARD BIOTECHNOLOGY INC. |
|
CB03 | Change of inventor or designer information |
Inventor after: Ma Runlin Inventor after: Chen Xiaojiang Inventor after: Liu Yongjiang Inventor before: Ma Runlin Inventor before: Chen Xiaojiang |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: MA RUNLIN CHEN XIAOJIANG TO: MA RUNLIN CHEN XIAOJIANG LIU YONGJIANG |
|
CP01 | Change in the name or title of a patent holder |
Address after: Longsheng industrial park No. 7 100176 street Beijing Rongchang economic and Technological Development Zone No. 2 building 201, unit 202 Patentee after: BEIJING KANGLEWEISHI BIOLOGICAL TECHNOLOGY CO.,LTD. Address before: Longsheng industrial park No. 7 100176 street Beijing Rongchang economic and Technological Development Zone No. 2 building 201, unit 202 Patentee before: BEIJING HEALTH GUARD BIOTECHNOLOGY Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20070103 |
|
CX01 | Expiry of patent term |